Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Behavior Disorders | 1 |
| Body Weight | 1 |
| Check Lists | 1 |
| Drug Therapy | 1 |
| Hyperactivity | 1 |
| Intelligence | 1 |
| Measures (Individuals) | 1 |
| Moderate Mental Retardation | 1 |
| Outcomes of Treatment | 1 |
| Patients | 1 |
| More ▼ | |
Source
| Journal of the American… | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkHanden, Benjamin L.; Hardan, Antonio Y. – Journal of the American Academy of Child & Adolescent Psychiatry, 2006
Objective: Olanzapine, an atypical antipsychotic, has been shown to be efficacious for treatment of psychotic and mood disorders in adults. This prospective, open-label study was conducted to examine the safety and usefulness of olanzapine in treating disruptive behavior disorders in adolescents with subaverage intelligence. Method: Sixteen…
Descriptors: Check Lists, Intelligence, Safety, Moderate Mental Retardation
